附属北京天坛医院-谷鸿秋导师介绍
谷鸿秋
副教授
硕士生导师
男
附属北京天坛医院
流行病与卫生统计学
临床试验设计与统计分析,预测性分析,证据合成,健康服务与医疗质量研究
guhongqiu@yeah.net
谷鸿秋，博士，副研究员，副教授，研究生导师。
主要研究领域为临床试验设计与统计分析、预测性分析、证据合成、健康服务与医疗质量研究及其在心、脑血管病领域的应用。此外，亦关注统计编程、数据可视化、可重复性研究、效率工具以及科研方法科普。
作为 PI, 主持国家自然科学基金、北京市医院管理中心、北京天坛医院多项科研项目 ，入选 2021 年北京市医院管理中心科研 “培育”人才计划及 “青苗” 人才计划。以一作/共一在 Sci Bull、JAMA Netw Open、eBioMedicine、Stroke、Lancet Reg Health West Pac、Eur J Neurol、Int J Stroke 等 SCI 期刊发表论著 30 余篇，并在 JAMA、JAMA Intern Med 、Stroke 等期刊发表多篇方法学评论文章。
兼任北京生物制品研究会生物统计专业委员会常务委员、北京慢病防治与健康教育研究会医疗健康大数据专业委员会委员、中国医疗器械行业协会医学数据分析专业委员会委员、中国卒中学会医疗质量管理与促进分会委员；Ann Intern Med、J Neurol Neurosurg Psychiatry、Eur J Neurol 、 Stroke Vasc Neurol 等多本 SCI 期刊以及 *中国循证心血管病杂志* 、*中国卒中杂志* 等多本核心期刊的编辑/审稿人。
出版《SAS 编程演义》、《The Little SAS Book 中文版》等统计编程专著，在个人科研方法科普微信公众号“统计札记”(StatsNotes)，发表统计、临床研究相关科普文章百余篇，累积受益 100 余万读者。
展开更多
科研项目
- 1. 国家卫生健康委医院管理研究所，医疗质量研究理论、方法及创新实践（编号：YLZLXZ23G113）, 202401-202412, 1 万元，主持，在研
- 2. 国家自然科学青年基金，基于医疗大数据与机器学习的缺血性卒中院内复发风险预测模型研究 （编号：72004146），202101-202312，24万元，主持，在研
- 3.北京市医院管理中心，基于医疗大数据与机器学习的缺血性卒中院内复发风险预测模型研究 （编号：PX2021024），202101-202312，15万元，主持，在研
- 4.北京市医院管理中心，基于炎症标志物的急性轻型缺血性卒中早期神经功能恶化预测模型研究（编号：QML20210501），202201 -202312，6万元，主持，在研
- 5.北京天坛医院青年基金，临床研究统计图表使用指南及软件程序包的开发（编号：2016-YQN-07），201701-201812，3万元，主持，结题
展开更多
研究成果
In English
1. Gu HQ, Wang CJ, Yang X, et al. Clinical characteristics, in-hospital management, and outcomes of patients with in-hospital vs. community-onset ischaemic stroke: a hospital-based cohort study. The Lancet Regional Health - Western Pacific. 2023;38:100890. doi: 10/gsnz6w
2. Wang CJ, Gu HQ, Zhang XM, et al. Temporal trends and rural–urban disparities in cerebrovascular risk factors, in-hospital management and outcomes in ischaemic strokes in China from 2005 to 2015: a nationwide serial cross-sectional survey. Stroke Vasc Neurol. 2023;8(1):34-50. doi:10.1136/svn-2022-001552
3. Gu H-Q, Wang C-J, Zhang X-M, Jiang Y, Li H, Meng X, Yang X, Liu L-P, Zhao X-Q, Wang Y-L, et al. Ten-year trends in sex differences in cardiovascular risk factors, in-hospital management, and outcomes of ischemic stroke in China: Analyses of a nationwide serial cross-sectional survey from 2005 to 2015. Int J Stroke. 2023;18:821–828. doi: 10.1177/17474930231158226
4. Wang CJ, Gu HQ, Zong LX, et al. Effectiveness of a Quality Improvement Intervention on Reperfusion Treatment for Patients With Acute Ischemic Stroke: A Stepped-Wedge Cluster Randomized Clinical Trial. JAMA Netw Open. 2023;6(6):e2316465. doi:10.1001/jamanetworkopen.2023.16465
5. Chen ZM, Gu HQ, Mo JL, et al. U-shaped association between low-density lipoprotein cholesterol levels and risk of all-cause mortality mediated by post-stroke infection in acute ischemic stroke. Sci Bull. Published online May 2023. doi:10/gr95f6
6. Gu HQ, Yang X, Li J, et al. Mediation effect of stroke recurrence in the association between post‐stroke interleukin‐6 and functional disability. CNS Neurosci Ther. Published online 2023. doi: 10.1111/cns.14289
7. Gu HQ. Rivaroxaban vs Apixaban and Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation. Jama-J Am Med Assoc. 2022; 327 (13): 1290. Doi: 10.1001/jama.2022.1425
8. Gu HQ, Wang CJ, Yang X, et al. Sex differences in vascular risk factors, in-hospital management, and outcomes of patients with acute ischemic stroke in China. Eur J Neurol. 2022; 29 (1): 188-198. Doi: 10.1111/ene.15124
9. Gu HQ, Yang KX, Lin JX, et al. Association between high-sensitivity C-reactive protein, functional disability, and stroke recurrence in patients with acute ischaemic stroke: A mediation analysis. eBiomedicine. 2022;80:104054. Doi: 10.1016/j.ebiom.2022.104054
10. Liu C, Gu HQ, Yang X, et al. Pre-stroke dementia and in-hospital outcomes in the Chinese Stroke Center Alliance. Ann Transl Med. 2022; 10 (19): 1050. Doi: 10.21037/atm-22-723
11. Wang HY, Gu HQ, Zhou Q, et al. Thrombolysis, time-to-treatment and in-hospital outcomes among young adults with ischaemic stroke in China: findings from a nationwide registry study in China. BMJ Open. 2022; 12 (6): e 055055. Doi: 10.1136/bmjopen-2021-055055
12. Wang YJ, Li ZX, Gu HQ, et al. China Stroke Statistics: an update on the 2019 report from the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations. Stroke Vasc Neurol. 2022; 7 (5): 415-450. Doi: 10.1136/svn-2021-001374
13. Weng JX, Gu HQ, Wang S, et al. External validation of ABCD series scores for predicting early stroke events following transient ischemic attack in a large nationwide registry. Eur Stroke J. 2022; 7 (4): 439-446. Doi: 10.1177/23969873221113145
14. Chen B, Gu HQ, Liu Y, et al. A model to predict the risk of mortality in severely ill COVID-19 patients. Comput Struct Biotec. 2021;19:1694-1700. Doi: 10.1016/j.csbj.2021.03.012
15. Chen B, Lu C, Gu HQ, et al. Serum Uric Acid Concentrations and Risk of Adverse Outcomes in Patients With COVID-19. Front Endocrinol. 2021;12:633767. Doi: 10.3389/fendo.2021.633767
16. Gu HQ, Wang J. Prediction Models for COVID-19 Need Further Improvements. JAMA Intern Med. 2021; 181 (1): 143-144. Doi: 10.1001/jamainternmed.2020.5740
17. Gu HQ, Yang KX, Yang X, et al. Guideline-directed low-density lipoprotein management in high-risk ischemic stroke or transient ischemic attack admissions in China from 2015 to 2019. Ann Transl Med. 2021; 9 (15): 1224. Doi: 10.21037/atm-21-1467
18. Gu HQ, Yang X, Wang CJ, et al. Assessment of Trends in Guideline-Based Oral Anticoagulant Prescription for Patients With Ischemic Stroke and Atrial Fibrillation in China. JAMA Netw Open. 2021; 4 (7): e 2118816. Doi: 10.1001/jamanetworkopen.2021.18816
19. Gu HQ, Yang X, Wang CJ, et al. Clinical Characteristics, Management, and In-Hospital Outcomes in Patients With Stroke or Transient Ischemic Attack in China. JAMA Netw Open. 2021; 4 (8): e 2120745. Doi: 10.1001/jamanetworkopen.2021.20745
20. Huang ZX, Gu HQ, Yang X, Wang CJ, Wang YJ, Li ZX. Risk factors for in-hospital mortality among acute ischemic stroke patients in China: a nationwide prospective study. Neurol Res. 2021; 43 (5): 387-395. Doi: 10.1080/01616412.2020.1866356
21. Li ZX, Xiong Y, Gu HQ, et al. P 2 Y 12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack. Stroke. 2021; 52 (7): 2250-2257. Doi: 10.1161/STROKEAHA.120.033040
22. Wang RR, Gu HQ, Wei YY, et al. Development and Validation of a Prognostic Model for One-year Survival of Cirrhosis Patients with First-ever Spontaneous Bacterial Peritonitis. J Clin Transl Hepato. 2021; 9 (5): 647-654. Doi: 10.14218/JCTH.2021.00031
23. Xiu Y, Gu H, Li X, et al. Incidence and Mortality of Acute Disseminated Encephalomyelitis in China: A Nationwide Population-Based Study. Neurosci Bull. 2021; 37 (6): 804-808. Doi: 10.1007/s12264-021-00642-740.
24. Gu HQ, Liu C. Clinical prediction models: evaluation matters. Ann Transl Med. 2020; 8 (4): 72. Doi: 10.21037/atm.2019.11.143
25. Gu HQ, Xie XW, Jing J, et al. Shuxuetong for Prevention of recurrence in Acute Cerebrovascular events with Embolism (SPACE) trial: rationale and design. Stroke Vasc Neurol. 2020; 5 (3): 311-314. Doi: 10.1136/svn-2019-000293
26. Wang YJ, Li ZX, Gu HQ, et al. China Stroke Statistics 2019: A Report From the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations. Stroke Vasc Neurol. 2020; 5 (3): 211-239. Doi: 10.1136/svn-2020-000457
27. Gu HQ, Liu LP. Letter by Gu and Liu Regarding Article, “HbA 1 c (Glycated Hemoglobin) Levels and Clinical Outcome Post-Mechanical Thrombectomy in Patients With Large Vessel Occlusion.” Stroke. 2019; 50 (6): e 171. Doi: 10.1161/STROKEAHA.119.025575
28. Gu HQ, Rao ZZ, Yang X, et al. Use of Emergency Medical Services and Timely Treatment Among Ischemic Stroke. Stroke. 2019; 50 (4): 1013-1016. Doi: 10.1161/STROKEAHA.118.024232
29. Gu HQ, Yang X, Rao ZZ, et al. Disparities in outcomes associated with rural-urban insurance status in China among inpatient women with stroke: a registry-based cohort study. Ann Transl Med. 2019; 7 (18): 426. Doi: 10.21037/atm.2019.08.125
30. Xie X, Gu HQ, Wang X, et al. Assessing the applicability of 2017 ACC/AHA hypertension guidelines for secondary stroke prevention in the BOSS study. J Clin Hypertens. 2019; 21 (10): 1534-1541. Doi: 10.1111/jch.13653
31. Yan R, Gu HQ, Wang W, Ma L, Li W, Group CR. Health-related quality of life in blood pressure control and blood lipid-lowering therapies: results from the CHIEF randomized controlled trial. Hypertens Res. 2019; 42 (10): 1561-1571. Doi: 10.1038/s41440-019-0281-z
32. Yang XM, Rao ZZ, Gu HQ, et al. Atrial Fibrillation Known Before or Detected After Stroke Share Similar Risk of Ischemic Stroke Recurrence and Death. Stroke. 2019; 50 (5): 1124-1129. Doi: 10.1161/STROKEAHA.118.024176
33. Gu HQ, Li DJ, Liu C, Rao ZZ. %ggBaseline: a SAS macro for analyzing and reporting baseline characteristics automatically in medical research. Ann Transl Med. 2018; 6 (16): 326. Doi: 10.21037/atm.2018.08.13
34. Gu HQ, Li ZX, Zhao XQ, et al. Insurance status and 1-year outcomes of stroke and transient ischaemic attack: a registry-based cohort study in China. Bmj Open. 2018; 8 (7): e021334. Doi: 10.1136/bmjopen-2017-021334
35. Gu H, Hua K, Li W, Wang Y, Yang J. Safety and efficacy of everolimus-eluting stent versus zotarolimus-eluting stent: A meta-analysis of randomized controlled clinical trials and observational studies. International journal of cardiology. 2015;201:552-560. doi: 10.1016/j.ijcard.2015.02.097
36. Gu H, Li W, Yang J, Wang Y, Bo J, Liu L. Hypertension prevalence, awareness, treatment and control among Han and four ethnic minorities (Uygur, Hui, Mongolian and Dai) in China. Journal of human hypertension. 2015;29(9): 555-560. doi: 10.1038/jhh.2014.123
In Chinese
1. Jin A,Qin Z, Shang H, Gu H. N-of-1 Trial. Chin J Stroke. 2023;18(03): 367-371.
2. Wang M, Wang C, Li Z, Gu H. Stepped Wedge Cluster Randomized Trials. Chin J Stroke. 2023; 18 (01): 114-122.
3. Zhou Q, Yang K, Jiang Y, Gu H. Registry-Based Randomized Clinical Trials. Chin J Stroke. 2022; 17 (10): 1145-1151.
4. Yang K, Zhou Q, Jiang Y, Gu H. Adaptive Design Randomized Controlled Clinical Trials. Chin J Stroke. 2022; 17 (10): 1152-1158.
5. Gu HQ, Yang X, Wang CJ, et al. Incidence, Risk Factors and In-hospital Outcomes of Symptomatic Seizures after Subarachnoid Hemorrhage: Analysis from China Stroke Center Alliance Registry Database. Chin J Stroke. 2020, 15 (06): 620-625.
6. Gu HQ, Wang CJ, Li ZX, et al. Comparison of Prediction Models for In-hospital Stroke Recurrence in Patients with Ischemic Stroke Based on Logistic Regression and XGBoost Methods. Chin J Stroke. 2020, 15 (06): 587-594.
7. Gu HQ, Wang JF, Zhang ZH, et al. Clinical Prediction Models: Basic Concepts, Application Scenarios, and Research Strategies. Chin J Evid Based Cardiovasc Med. 2018, 10 (12): 1454-62.
8. Gu HQ, Wang JF, Zhang ZH, et al. Clinical Prediction Models: Model Development. Chin J Evid Based Cardiovasc Med. 2019, 11 (1): 9-12.
9. Wang JF, Zhang ZH, Zhou ZR,Gu HQ. Clinical Prediction Models: Model Validation. Chin J Evid Based Cardiovasc Med. 2019, 11 (2): 145-8.
10. Gu HQ. A brief introduction of statistical analysis strategy and statistical charts for clinical research. Chin J Evid Based Cardiovasc Med. 2018, 10 (7): 785-8.
11. Gu H. Statistical methods and statistical charts for baseline information in clinical research. Chin J Evid Based Cardiovasc Med. 2018, 10 (8): 910-2.
12. Gu H. Statistical methods and statistical charts for effect estimation in clinical research. Chin J Evid Based Cardiovasc Med. 2018, 10 (9): 1048-52.
13. Gu H. Statistical strategy and statistical charts for sensitivity analyses in clinical research. Chin J Evid Based Cardiovasc Med. 2018, 10 (10): 1171-5.
14. Gu H. Statistical strategy and statistical charts for risk factors analysis in clinical research. Chin J Evid Based Cardiovasc Med. 2018, 10 (11): 1292-4.
15. Gu H, Li W, Wang Y. Standardization and adjustment of Rate in epidemiology study: methodology and SAS macro code. Chin J Dis Control Prev. 2014,18 : 557-60.
16. Gu H, Wang Y, Li W. Progress on methodology of adjusting survival curves. Chin J Epidemiol. 2014;35:97-9.
17. Gu H, Wang Y, Li W. Application of the Cochrane Collaboration’s tool for assessing risk of bias in meta-analysis of randomized controlled trails. Chinese Circulation Journal. 2014;29:147-9.
18. Gu H, Li W. How to understand the adjustment of “Rate” in epidemiology studies. Chinese Circulation Journal. 2013;28:155.
19. Gu H, Pang L, Liu E, Yin W, Luo W, Wang C, Cao X, Rou K and Wu Z. Effectivness of integrated and intensified intervention on increasing methadone dose among clients of methadone maintenance treatment (MMT) in China. Chin J AIDS & STD. 2011;17:636-9.
展开更多
学校介绍
首都医科大学建校于1960年，是北京市重点高等院校，著名泌尿外科专家、中国科学院院士、中国工程院院士、原全国人大常委会副委员长吴阶平教授为首任院长。学校由校本部和附属医院(即临床医学院)组成。校本部设有基础医学院、生物医学工程学院、公共卫生与家庭医学学院、高等职业教育学院、中医药学院、顺义校区、继续教育学院、护理学院、卫生事业管理与发展学院及首都医科大学国际教学部；附属医院包括宣武医院(第一临床医学院)、附属北京友谊医院(第二临床医学院)、附属北京朝阳医院(第三临床医学院)、附属北京同仁医院(第四临床医学院)、附属北京天坛医院(第五临床医学院)、附属北京安贞医院(第六临床医学院)、附属北京口腔医院(口腔医学院)、附属北京儿童医院(儿科医学院)、附属北京妇产医院(妇产医学院)、附属北京安定医院(精神卫生学院)、附属复兴医院(第八临床医学院)、附属北京中医医院(中医药临床医学院)和康复医学院。
学校和附属医院现有教职员工和医护人员22575人。有院士4人，正高职称700余人，副高职称1800余人。学校学科专业齐全，学科力量雄厚，在基础和临床各专业拥有一大批具有很高造诣的专家学者，现有3个国家级重点学科，有38个博士学位授予权学科，58个硕士学位授予权学科和2个博士后科研流动站。
校本部和附属医院总占地面积97.3万平方米，总建筑面积134万平方米 ，固定资产总值近46.5亿元，图书馆藏书108.3万册 ，住院病床10039张。学校开办的七年制专业中设有临床医学和口腔医学；五年制专业中设有临床医学、口腔医学、预防医学、护理学、中医学等；四年制专业中设有生物医学工程、中药学和康复治疗学。在临床医学专业中设有儿科医学、康复医学、医学影像、精神卫生与精神病学和医学检验5个专业方向；在生物医学工程专业中设有医学影像设备与技术和听力学专业方向。高等职业教育设有护理、医学检验、药学、医学影像技术、康复技术、口腔修复工艺、眼科验光、实验动物技术、中医学、中药制剂、医学信息、临床医学、预防医学、中药经营贸易和中医学美容专业方向15个专业。首都医科大学现已成为以培养高层次本科生与研究生为核心、以临床应用型人才为主和培养预防、康复、生物医学工程和医学基础各学科、各层次人才，位于全国先进医学院校行列的高等学府。
学校具有较强的学术发展与科研实力，在校本部和附属医院建有一批国家级和市级重点学科和重点实验室，建有高水平的国家级或市级研究和培训机构，如卫生部全科医学培训中心、临床医学研究所、基础医学研究所、神经科学研究所、眼科研究所、老年病医疗研究中心、泌尿外科研究所、心肺血管医疗研究中心、生命科学院、卫生毒理检测中心、生物工程技术研究中心、祖国医学研究所、临床疾病研究中心、中医肝病临床研究中心、生殖医学研究所、心血管疾病临床试验及社区干预中心和北京市卫生政策与卫生经济研究中心等。神经生物学、细胞生物学、电生理学、基础免疫学、实验寄生虫学、医学图像处理、生物医学、信息检测与处理、神经内科、神经外科、心脏内外科、肾移植、呼吸和消化内科、口腔颌面外科、眼科、耳鼻咽喉科、小儿血液病等领域在国内外享有较高声誉，很多学科的研究和医疗水平已经达到或接近国际先进水平。
学校十分重视对外交流与合作，改革开放以来，先后与世界20多个国家和地区签定了友好交流协议， 近十年中,先后接待美国、加拿大、英国、澳大利亚、法国、瑞典、日本、荷兰、意大利、德国、丹麦及台湾、香港和澳门等50多个国家和地区的专家学者8000余人次来校进行学术交流和参观访问。同时，学校积极选送教师、科研人员和管理干部出国进修、参加学术会议和考察访问。
展开更多